Oncolytic parvoviruses as cancer therapeutics.
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
Rommelaere
Jean
J
Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany. j.rommelaere@dkfz.de
Geletneky
Karsten
K
Angelova
Assia L
AL
Daeffler
Laurent
L
Dinsart
Christiane
C
Kiprianova
Irina
I
Schlehofer
Joerg R
JR
Raykov
Zahari
Z
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism; D009369:Neoplasms / Q000473:pathology / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses; D017992:Parvovirus / Q000235:genetics / Q000502:physiology
D007155:Immunologic Factors